Clinical trials: Esophagogastric Cancer
Gastric and Esophagogastric Junction Adenocarcinoma
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma…
- Trial name
- VESTIGE (NCT03443856)
- Testing
- Nivolumab and Ipilimumab, chemotherapy
- Where
- 28 sites in Czechia, France and 7 more
- Volunteers
- 197 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oesophagus Cancer, Barrett Esophagus
Classification of Adenocarcinoma of the Esophagogastric Junction
The Siewert classification of oesophageal cancer is the standard approach in anatomically subdividing cancer of the lower oesohagus.
- Conditions
- Oesophagus Cancer, Barrett Esophagus, Siewert Type I Adenocarcinoma of Esophagogastric Junction, Siewert Type II Adenocarcinoma of Esophagogastric Junction
- Trial name
- NCT04151524
- Where
- Ireland
- Volunteers
- 1,658 people
- Sponsor
- St. James's Hospital, Ireland
Cancer of Stomach, Cancer of Esophagus
Audit of the Spanish EURECCA Esophagogastric Cancer Registry
Objective. The objective of the study is to verify and validate the data collected in the Spanish EURECCA (EUropean REgistry of Cancer CAre) Esophagogastric Cancer Registry between January 2014 and December 2017 through an audit…
- Trial name
- NCT03541629
- Where
- 11 sites in Spain
- Volunteers
- 1,839 people
- Sponsor
- Parc de Salut Mar
Patients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction
Radiomics-based Models for the Prediction of Pathological Response to Neoadjuvant Therapy in Gastric and Gastroesophageal Cancer
Identifying predictors of response to neoadjuvant therapy in gastric and gastro-oesophageal cancer early in the history of the disease would ensure optimal treatment planning.
- Trial name
- RADI-S (NCT06044961)
- Testing
- CT scan
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Oesophagogastric Cancer
IMaC - Immune Pathways in Oesophagogastric Cancer
The number of cases of oesophagogastric cancer is increasing every year. Currently, only 39% of patients with oesophageal cancer can have potentially curative treatment by the time they are diagnosed.
- Trial name
- IMaC (NCT06057220)
- Testing
- No intervention sample collection only
- Where
- 3 sites in United Kingdom
- Volunteers
- 310 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Esophagus Cancer, Gastric Cancer
HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes
Targeted therapies offer promise to improve oncologic outcomes in esophagogastric adenocarcinoma (EGA). The landmark 'Trastuzumab for gastric cancer (ToGA)' trial established the therapeutic value of Human Epidermal Growth Factor…
- Conditions
- Esophagus Cancer, Gastric Cancer, HER2-positive Cancer, HER2-low Cancer
- Trial name
- HERA (NCT06550063)
- Where
- Ireland
- Volunteers
- 2,188 people
- Sponsor
- St. James's Hospital, Ireland